Patient demographics by dose-level cohort
| . | Pomalidomide dose levels . | ||||
|---|---|---|---|---|---|
| . | 2 mg (n = 6) . | 3 mg (n = 8) . | 4 mg (n = 14) . | 5 mg (n = 10) . | Total (N = 38) . |
| Mean age, years (range) | 64.7 (55-72) | 70.4 (61-78) | 67.5 (45-80) | 61.3 (38-83) | 66.0 (38-83) |
| Age ≥75 y, % | 0 | 25 | 21 | 10 | 16 |
| Male, % | 17 | 38 | 71 | 40 | 47 |
| Caucasian, % | 83 | 100 | 100 | 80 | 92 |
| Durie-Salmon stage at enrollment, n (%) | |||||
| I | 1 (17) | 1 (13) | 3 (21) | 2 (20) | 7 (18) |
| II | 0 | 1 (13) | 4 (29) | 1 (10) | 6 (16) |
| III | 5 (83) | 6 (75) | 7 (50) | 7 (70) | 25 (66) |
| Median duration of active multiple myeloma, years (range) | 4.5 (2.8-14.0) | 5.9 (2.6-12.0) | 5.4 (2.0-23.4) | 5.9 (1.4-10.9) | 5.5 (1.4-23.4) |
| Median number of prior therapies, n (range) | 7.0 (5-11) | 6.5 (2-11) | 6.0 (3-17) | 5.5 (3-10) | 6 (2-17) |
| Prior lenalidomide and bortezomib, n (%) | 6 (100) | 8 (100) | 14 (100) | 10 (100) | 38 (100) |
| Refractory to lenalidomide | 4 (67) | 8 (100) | 12 (86) | 7 (70) | 31 (82) |
| Refractory to lenalidomide as last regimen | 1 (17) | 3 (38) | 5 (36) | 2 (20) | 11 (29%) |
| Refractory to bortezomib | 3 (50) | 7 (88) | 10 (71) | 8 (80) | 28 (74) |
| Refractory to bortezomib as last regimen | 2 (33) | 4 (50) | 7 (50) | 7 (70) | 20 (53) |
| Refractory to both | 3 (50) | 7 (88) | 8 (57) | 6 (60) | 24 (63) |
| Prior carfilzomib, n (%) | 3 (50) | 4 (50) | 3 (21) | 2 (20) | 12 (32) |
| Refractory to carfilzomib | 3 (50) | 3 (38) | 4 (29) | 2 (20) | 12 (32) |
| Prior dexamethasone, n (%) | 6 (100) | 8 (100) | 14 (100) | 10 (100) | 38 (100) |
| Prior thalidomide, n (%) | 4 (67) | 6 (75) | 11 (79) | 9 (90) | 30 (79) |
| Prior stem cell transplantation, n (%) | 4 (67) | 4 (50) | 11 (79) | 6 (60) | 25 (66) |
| . | Pomalidomide dose levels . | ||||
|---|---|---|---|---|---|
| . | 2 mg (n = 6) . | 3 mg (n = 8) . | 4 mg (n = 14) . | 5 mg (n = 10) . | Total (N = 38) . |
| Mean age, years (range) | 64.7 (55-72) | 70.4 (61-78) | 67.5 (45-80) | 61.3 (38-83) | 66.0 (38-83) |
| Age ≥75 y, % | 0 | 25 | 21 | 10 | 16 |
| Male, % | 17 | 38 | 71 | 40 | 47 |
| Caucasian, % | 83 | 100 | 100 | 80 | 92 |
| Durie-Salmon stage at enrollment, n (%) | |||||
| I | 1 (17) | 1 (13) | 3 (21) | 2 (20) | 7 (18) |
| II | 0 | 1 (13) | 4 (29) | 1 (10) | 6 (16) |
| III | 5 (83) | 6 (75) | 7 (50) | 7 (70) | 25 (66) |
| Median duration of active multiple myeloma, years (range) | 4.5 (2.8-14.0) | 5.9 (2.6-12.0) | 5.4 (2.0-23.4) | 5.9 (1.4-10.9) | 5.5 (1.4-23.4) |
| Median number of prior therapies, n (range) | 7.0 (5-11) | 6.5 (2-11) | 6.0 (3-17) | 5.5 (3-10) | 6 (2-17) |
| Prior lenalidomide and bortezomib, n (%) | 6 (100) | 8 (100) | 14 (100) | 10 (100) | 38 (100) |
| Refractory to lenalidomide | 4 (67) | 8 (100) | 12 (86) | 7 (70) | 31 (82) |
| Refractory to lenalidomide as last regimen | 1 (17) | 3 (38) | 5 (36) | 2 (20) | 11 (29%) |
| Refractory to bortezomib | 3 (50) | 7 (88) | 10 (71) | 8 (80) | 28 (74) |
| Refractory to bortezomib as last regimen | 2 (33) | 4 (50) | 7 (50) | 7 (70) | 20 (53) |
| Refractory to both | 3 (50) | 7 (88) | 8 (57) | 6 (60) | 24 (63) |
| Prior carfilzomib, n (%) | 3 (50) | 4 (50) | 3 (21) | 2 (20) | 12 (32) |
| Refractory to carfilzomib | 3 (50) | 3 (38) | 4 (29) | 2 (20) | 12 (32) |
| Prior dexamethasone, n (%) | 6 (100) | 8 (100) | 14 (100) | 10 (100) | 38 (100) |
| Prior thalidomide, n (%) | 4 (67) | 6 (75) | 11 (79) | 9 (90) | 30 (79) |
| Prior stem cell transplantation, n (%) | 4 (67) | 4 (50) | 11 (79) | 6 (60) | 25 (66) |